1Clarke CE, Guttman M. Dopamine agonist monotherapy in Parkinson's disease[J]. Lancet, 2002, 360(9347): 1767-1769. 被引量：1
2Pahwa R, Factor SA, Lyons KE, et al. Practice parameter: treatment of Parkinson disease with motor fluctuations and dyskinesia (an evidence-based review) report of the Quality Standards Subcommittee of the American Academy of Neurology[J]. Neurology, 2006, 66(7):983-995. 被引量：1
3National Collaborating Centre for Chronic Conditions.Parkinson's disease: national clinical guideline for diagnosis and management in primary and secondary care[M]. London: Royal College of Physicians, 2006:62-64. 被引量：1
4Daniels CE. Pramipexole (Mirapex): a brief review[EB/OL]. http://clinicalcenter.nih.gov/phar/updates/Feb-Update01 .pdf. 被引量：1
5Reichmann H, Brecht MH, Koster J, et al. Pramipexole in routine clinical practice: a prospective observational trial in Parkinson's disease[J]. CNS Drugs, 2003, 17(13):965-973. 被引量：1
6Holloway RG, Shoulson I, Fahn S, et al. Pramipexole vs levodopa as initial treatrnent for Parkinson disease: a 4-year randomized controlled trial[J]. Arch Neurol, 2004,61(7):1044-1053. 被引量：1
7Parkinson Study Group. Pramipexole vs levodopa as initial treatrnent for Parkinson disease: A randomized controlled trial. Parkinson Study Group [J]. JAMA, 2000,284(15): 1931-1938. 被引量：1
8Lieberman A, Ranhosky A, Korts D. Clinical evaluation of pramipexole in advanced Parkinson's disease: results of a double-blind, placebo-controlled,parallel-group study[J]. Neurology, 1997, 49(1): 162-168. 被引量：1
10Moller JC, Oertel WH, Koster J. Long-term efficacy and safety of pramipexole in advanced Parkinson's disease:results from a European multicenter trial[J]. Mov Disord,2005, 20(5):602-610. 被引量：1
二级参考文献9
1Mizuno Y,Yanagisawa N,Kuno S,et al.Randomized,doubleblind study of pramipexole with placebo and bromocriptine in advanced Parkinson's disease.Mov Disord,2003,18:1149-1156. 被引量：1
2Pinter MM,Rutgers AW,Hebenstreit E,et al.An open-label,multicentre clinical trial to determine the levodopa dose-sparing capacity of Pramipexole in patients with idiopathic Parkinson's disease.J Neural Transm,2000,107:1307-1323. 被引量：1
3Reichmann H,Brecht MH,Koster J,et al.Pramipexole in routine clinical practice:a prospective observational trial in Parkinson's disease.CNS Drugs,2003,17:965-973. 被引量：1
4Holloway RG,Shoulson I,Fahn S,et al.Pramipexole vs levodopa as initial treatment for Parkinson's disease:a 4-year randomized controlled trial.Arch Neurol,2004,61:1044-1053. 被引量：1
5Linazasoro G,Spanish Dopamine Agonists Study Group.Conversion from dopamine agoists to Pramipexole.An open-label trial in 227 patients with advanced Parkinson's disease.J Neurol,2004,251:335-339. 被引量：1
6Gu M,Iravani MM,Cooper JM,et al.Pramipexole protects against apoptotic cell death by non-dopaminergic mechanisms.J Neurochem,2004,91:1075-1081. 被引量：1
7Asanuma M,Miyazaki I,Diaz-Corrales FJ,et al.Pramipexole has ameliorating effects on levodopa-induced abnormal dopamine turnover in parkinsonian striatum and quenching effects on dopaminesemiquinone generated in vitro.Neurol Res,2005,27:533-539. 被引量：1
8Moller JC,Oertel WH,Koster J,et al.Long-term efficacy and safety of pramipexole in advanced Parkinson's disease:results from a European multicenter trial.Mov Disord,2005,20:602-610. 被引量：1
9Mierau J,Schingnitz G.Biochemical and Pharmacological studies on Pramipxole,a potent and selective D2 receptor agonist.Eur J Pharmacol,1992,215:161-170. 被引量：1
